ROBOSENSE
RoboSense officially announced the SOP version of the high-performance, automotive-grade, MEMS solid-state LiDAR RS-LiDAR-M1 at CES 2021. In the past five years of research and development, M1 has gone through dozens of iterations and has been presented at the CES for 4 consecutive years winning two CES Innovation Awards. Since July 2020, M1 has received a number of orders for serial production cars worldwide. It has been delivered to OEM partners in batches in December 2020, becoming the world's first mass-production-ready solid-state automotive LiDAR.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005687/en/
The development process of M1 has been finalized after completing the processes of product requirement definition, components selection, design and development, repeated verification tests and manufacturing. The SOP version’s features include:
- The ranging capability reaches more than 150m for 10% reflectivity targets (with range up to 200 meters for detecting vehicle objects). The average resolution of M1 is 0.2°x0.2° (horizontally and vertically) with an ultra-wide field of view 120°×25° (horizontally and vertically) to create a high resolution of 0.75M pixel points per second.
- The RS-LiDAR-M1 has reduced the minimum detection distance to less than 0.5 meters through upgrading the optical system design and signal processing system.
- RoboSense has innovated the signal processing algorithms and optical system design, which has enabled the M1 to distinguish laser emission signals from ambient lights, without further concern of strong sunlight interference.
- M1 uses the unique technologies to filter laser pulses from other LiDARs to prevent multiple LiDAR crosstalk.
- The SOP version of M1 has reduced the size compared to the last version. Up to now, it is the world’s thinnest automotive LiDAR, with a size of 108mm(Depth) x 110mm(Width) x 45mm(Height) to make the integration into the vehicle body easy.
- Power consumption is reduced to less than 15W.
- M1 provides a series of supporting functions, including OTA firmware updating, blockage detection, smart cleaning, smart heating, performance detection, power management, network management, etc.
- RoboSense strictly abides by the ISO26262 safety standard, and has integrated the fail-safe concept and technology from aerospace and rail transportation systems, achieving all-round monitoring of various system modules such as laser emitter and receiver, MEMS control, point cloud processing and transmitting, etc. Its safety mechanism has covered thousands of failure modes, fully achieving the requirements of ASIL-B and SIL-2.
- RoboSense has adopted VDA6.3 as the basis of project management and control, fully implemented the requirements of IATF16949 quality management system and ISO26262 standard, and has integrated ISO16750 and other automotive-grade reliability specifications, to carry out a series of verification tests on M1, including random mechanical vibration, mechanical shock, splash water, stone impact, high and low temperature storage and operation, solar radiation, EMC, chemical corrosion, salt spray and others. The cumulative test time of all M1 test samples has exceeded 300,000 hours, the longest-running prototype has been in continuous operation for more than 700 days, and the total road test mileage has exceeded 200,000 kilometers.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. http://robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
